TYME · Tyme Technologies, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $13.44M | $17.03M | $12.96M | $14.72M | $8.84M | $6.11M |
| SG&A | $9.63M | $10.19M | $12.80M | $14.59M | $10.52M | $9.10M |
| Total Operating Expenses | $25.51M | $27.22M | $25.76M | $31.78M | $19.36M | $15.21M |
| D&A | - | $5.2K | $5.2K | $8.4K | $4.3K | $4.3K |
| Operating Income | ($25.51M) | ($27.22M) | ($25.76M) | ($31.78M) | ($19.36M) | ($15.21M) |
| Interest Expense | $70.2K | $97.1K | $114.2K | - | $3.50M | - |
| Income Tax | - | - | - | - | $0 | - |
| Net Income | ($23.63M) | ($28.98M) | ($22.00M) | ($32.98M) | ($18.97M) | ($15.21M) |
| EPS - Basic | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.74M | $107.52M | $26.70M | $14.30M | $9.7K | $10.48M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $78.90M | $109.66M | $28.08M | $16.14M | $31.01M | $10.71M |
| Total Assets | $88.02M | $110.26M | $29.50M | $17.52M | $31.02M | $10.72M |
| Current Liabilities | $7.39M | $5.64M | $5.58M | $6.31M | $4.55M | $3.33M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $7.93M | $8.47M | $10.48M | $7.85M | $4.55M | $3.33M |
| Stockholders' Equity | $80.08M | $101.80M | $19.03M | $9.67M | $26.47M | $7.39M |
| Retained Earnings | ($160.42M) | ($136.79M) | ($107.82M) | ($85.81M) | ($52.83M) | ($33.86M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($21.24M) | ($23.56M) | ($19.56M) | ($20.12M) | ($5.86M) | ($5.86M) |
| Investing Cash Flow | ($72.54M) | - | - | ($15.5K) | - | - |
| Financing Cash Flow | $6.2K | $104.38M | $31.96M | $5.46M | $30.37M | $10.24M |
| CapEx | - | - | - | $15.5K | - | - |
| Free Cash Flow | - | - | - | ($20.13M) | - | - |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | 0.61 | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -26.8% | -26.3% | -74.6% | -188.3% | -61.2% | -141.9% |
| Return on equity | -29.5% | -28.5% | -115.6% | -341.2% | -71.7% | -205.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 10.68 | 19.43 | 5.03 | 2.56 | 6.82 | 3.22 |
| Quick ratio | 10.68 | 19.43 | 5.03 | 2.56 | 6.82 | 3.22 |
| Cash ratio | 1.86 | 19.05 | 4.78 | 2.27 | 0.00 | 3.15 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -363.2x | -280.2x | -225.5x | - | -5.5x | - |
| Equity multiplier | 1.10 | 1.08 | 1.55 | 1.81 | 1.17 | 1.45 |
| Liabilities / Assets | 0.09 | 0.08 | 0.36 | 0.45 | 0.15 | 0.31 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 6.3% | -5.7% | 18.9% | -64.1% | -27.3% | - |
| Net income growth (YoY) | 18.5% | -31.7% | 33.3% | -73.9% | -24.7% | - |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -21.3% | 435.1% | 96.8% | -63.5% | 258.1% | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing TYME TECHNOLOGIES against the 5 most active filers in the same SIC group.